Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 12

1.

Use and costs of medical care for children and adolescents with and without attention-deficit/hyperactivity disorder.

Leibson CL, Katusic SK, Barbaresi WJ, Ransom J, O'Brien PC.

JAMA. 2001 Jan 3;285(1):60-6.

PMID:
11150110
2.

Ambulatory health care visits by children: principal diagnosis and place of visit.

Freid VM, Makuc DM, Rooks RN.

Vital Health Stat 13. 1998 May;(137):1-23. Review.

3.

The economic impact of attention-deficit/hyperactivity disorder in children and adolescents.

Pelham WE, Foster EM, Robb JA.

Ambul Pediatr. 2007 Jan-Feb;7(1 Suppl):121-31. Review.

PMID:
17261491
4.

The economic impact of attention-deficit/hyperactivity disorder in children and adolescents.

Pelham WE, Foster EM, Robb JA.

J Pediatr Psychol. 2007 Jul;32(6):711-27. Epub 2007 Jun 7. Review.

PMID:
17556402
5.

Economic implications of attention-deficit hyperactivity disorder for healthcare systems.

Leibson CL, Long KH.

Pharmacoeconomics. 2003;21(17):1239-62. Review.

PMID:
14986737
6.

Economic impact of childhood and adult attention-deficit/hyperactivity disorder in the United States.

Doshi JA, Hodgkins P, Kahle J, Sikirica V, Cangelosi MJ, Setyawan J, Erder MH, Neumann PJ.

J Am Acad Child Adolesc Psychiatry. 2012 Oct;51(10):990-1002.e2. doi: 10.1016/j.jaac.2012.07.008. Epub 2012 Sep 5. Review.

PMID:
23021476
7.

Cost effectiveness of pharmacotherapies for attention-deficit hyperactivity disorder: a systematic literature review.

Wu EQ, Hodgkins P, Ben-Hamadi R, Setyawan J, Xie J, Sikirica V, Du EX, Yan SY, Erder MH.

CNS Drugs. 2012 Jul 1;26(7):581-600. doi: 10.2165/11633900-000000000-00000. Review.

PMID:
22712698
8.

Parent training interventions for Attention Deficit Hyperactivity Disorder (ADHD) in children aged 5 to 18 years.

Zwi M, Jones H, Thorgaard C, York A, Dennis JA.

Cochrane Database Syst Rev. 2011 Dec 7;(12):CD003018. doi: 10.1002/14651858.CD003018.pub3. Review.

PMID:
22161373
9.

Tricyclic antidepressants for attention deficit hyperactivity disorder (ADHD) in children and adolescents.

Otasowie J, Castells X, Ehimare UP, Smith CH.

Cochrane Database Syst Rev. 2014 Sep 19;(9):CD006997. doi: 10.1002/14651858.CD006997.pub2. Review.

PMID:
25238582
10.

Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents.

Gillies D, Sinn JKh, Lad SS, Leach MJ, Ross MJ.

Cochrane Database Syst Rev. 2012 Jul 11;(7):CD007986. doi: 10.1002/14651858.CD007986.pub2. Review.

PMID:
22786509
11.

Attention-deficit/hyperactivity disorder in children and adolescents: interventions for a complex costly clinical conundrum.

Greydanus DE, Pratt HD, Sloane MA, Rappley MD.

Pediatr Clin North Am. 2003 Oct;50(5):1049-92, vi. Review.

PMID:
14558681
12.

[The health economics of attention deficit hyperactivity disorder in Germany. Part 1: Health care utilization and cost of illness].

Schlander M, Trott GE, Schwarz O.

Nervenarzt. 2010 Mar;81(3):289-300. Review. German.

PMID:
20232510

Supplemental Content

Support Center